A Brief Review: Current Developments In Immunotherapy For Cancer Prevention

Isha P. Bhadke , Khushi D. Shinde , Nikita V. Mahalle , Harigopal S. Sawarkar , Neha L. Zod

Keywords: Cancer, Immunotherapy, Monoclonal Antibodies, Rituximab, etc.

The depth exploration of advancements in immunotherapy for cancer prevention, with a particular emphasis on monoclonal antibody (mAb)-based therapies. Monoclonal antibodies, known for their specificity and adaptability, have become pivotal in targeted cancer therapy. The development of hybridoma technology in the 1970s revolutionized therapeutic approaches by allowing for the production of antigen-specific antibodies. Through significant advancements in mAb technology, therapeutic approaches have expanded to include rodent mAb technology, phage display, and the successful integration of mAbs with chemotherapy and immunotherapy agents. Rituximab, a chimeric mAb, exemplifies these advancements, showing efficacy in treating CD20+ malignancies, especially in non-Hodgkin's lymphoma. This review highlights the mechanisms of action of these mAbs, including complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, and apoptosis induction, while examining combination approaches with immune modulators and chemotherapeutic agents. By addressing the challenges and future directions, this review contributes to understanding the role of immunotherapy in advancing cancer prevention and treatment.

Published Paper   E-Certificate

"A Brief Review: Current Developments In Immunotherapy For Cancer Prevention", IJSDR - International Journal of Scientific Development and Research (www.IJSDR.org), ISSN:2455-2631, Vol.9, Issue 11, page no.413 - 420, November-2024, Available :https://ijsdr.org/papers/IJSDR2411053.pdf

Volume 9 Issue 11, November-2024

Pages : 413 - 420

Paper Reg. ID: IJSDR_212742

Published Paper Id: IJSDR2411053

Downloads: 000346998

Research Area: Pharmacy

Country: Amravati, Maharashtra, India

Published Paper PDF: https://ijsdr.org/papers/IJSDR2411053

Published Paper URL: https://ijsdr.org/viewpaperforall?paper=IJSDR2411053

ISSN: 2455-2631 | IMPACT FACTOR: 9.15 Calculated By Google Scholar | ESTD YEAR: 2016

An International Scholarly Open Access Journal, Peer-Reviewed, Refereed Journal Impact Factor 9.15 Calculate by Google Scholar and Semantic Scholar | AI-Powered Research Tool, Multidisciplinary, Monthly, Multilanguage Journal Indexing in All Major Database & Metadata, Citation Generator

Publisher: IJSDR(IJ Publication) Janvi Wave

This work is licensed under a Creative Commons Attribution 4.0 International License and The Open Definition